Who owns BioAge Labs, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of BIOA from SEC Form 13F filings across 162 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 162 institutions disclosed 35.9M shares of BioAge Labs, Inc. worth $254.5M — about 78.3% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
162
13F holders
$254.5M
value, 2026 filers
78.3%
of shares outstanding (35.9M sh)
47
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of BIOA's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3.5M | $25.1M | 0.0% | 7.7% | +24.3% |
| 2 | a16z Capital Management, L.L.C. | 3.2M | $22.9M | 0.1% | 7% | 0.0% |
| 3 | Sofinnova Investments, Inc. | 2.3M | $16.3M | 0.7% | 5% | 0.0% |
| 4 | Cormorant Asset Management, LP | 2.2M | $15.9M | 1.1% | 4.9% | -6.3% |
| 5 | MPM BIOIMPACT LLC | 1.9M | $13.2M | 1.0% | 4% | +11.3% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 1.6M | $11.5M | 0.0% | 3.5% | +5.0% |
| 7 | STATE STREET CORP | 1.3M | $9.6M | 0.0% | 2.9% | +32.0% |
| 8 | Octagon Capital Advisors LP | 1.3M | $9.2M | 1.2% | 2.8% | -25.6% |
| 9 | D. E. Shaw & Co., Inc. | 1.2M | $8.2M | 0.0% | 2.5% | +55.7% |
| 10 | Polar Capital Holdings Plc | 1.1M | $7.6M | 0.0% | 2.3% | -0.3% |
| 11 | BRAIDWELL LP | 1.0M | $7.3M | 0.3% | 2.3% | 0.0% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 921,507 | $6.5M | 0.0% | 2% | -8.2% |
| 13 | Sands Capital Alternatives, LLC | 786,353 | $5.6M | 0.8% | 1.7% | 0.0% |
| 14 | JPMORGAN CHASE & CO | 782,508 | $5.6M | 0.0% | 1.7% | +234.4% |
| 15 | ORBIMED ADVISORS LLC | 711,811 | $5.0M | 0.1% | 1.6% | -5.4% |
| 16 | Pivotal bioVenture Partners Investment Advisor LLC | 653,374 | $4.6M | 1.8% | 1.4% | 0.0% |
| 17 | MILLENNIUM MANAGEMENT LLC | 636,546 | $4.5M | 0.0% | 1.4% | +185.9% |
| 18 | RENAISSANCE TECHNOLOGIES LLC | 626,661 | $4.4M | 0.0% | 1.4% | +278.2% |
| 19 | MORGAN STANLEY | 532,070 | $3.8M | 0.0% | 1.2% | +88.4% |
| 20 | COSMIC MANAGEMENT, LLC | 501,833 | $3.6M | 1.1% | 1.1% | 0.0% |
| 21 | DIMENSIONAL FUND ADVISORS LP | 499,916 | $3.5M | 0.0% | 1.1% | +26.8% |
| 22 | Qube Research & Technologies LtdNEW | 483,993 | $3.4M | 0.0% | 1.1% | new |
| 23 | VANGUARD PORTFOLIO MANAGEMENT LLC | 406,096 | $2.9M | 0.0% | 0.9% | -1.0% |
| 24 | FRANKLIN TEMPLETON INC | 378,467 | $2.3M | 0.0% | 0.8% | +34.2% |
| 25 | Nuveen, LLC | 338,789 | $2.4M | 0.0% | 0.7% | -3.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.